Chloroquine is a potent pulmonary vasodilator that attenuates hypoxia‐induced pulmonary hypertension
British Journal of Pharmacology2017Vol. 174(22), pp. 4155–4172
Citations Over TimeTop 13% of 2017 papers
Kang Wu, Qian Zhang, Xiongting Wu, Wenju Lu, Haiyang Tang, Zhihao Liang, Yali Gu, Shanshan Song, Ramon J. Ayon, Ziyi Wang, Kimberly M. McDermott, Angela Balistrieri, Christina Wang, Stephen M. Black, Joe G. N. Garcia, Ayako Makino, Jason X.‐J. Yuan, Jian Wang
Abstract
Chloroquine is a potent pulmonary vasodilator that may directly or indirectly block VDCC, store-operated Ca2+ channels and receptor-operated Ca2+ channels in PASMC. The therapeutic potential of chloroquine in pulmonary hypertension is probably due to the combination of its vasodilator, anti-proliferative and anti-autophagic effects.
Related Papers
- → Dependency of hypoxic pulmonary vasoconstriction on temperature(1977)97 cited
- → Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies(2004)44 cited
- → Release of vasodilator prostaglandin, PGI2, from isolated rat lung during vasoconstriction.(1981)126 cited
- → Potential Role of Arachidonic Acid Metabolites in Hypoxic Pulmonary Vasoconstriction(1985)16 cited
- → Pindolol inhibits the development of hypoxic pulmonary vasoconstriction(1990)